Last kr53.00 SEK
Change Today -1.50 / -2.75%
Volume 49.2K
NVP On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
Frankfurt
As of 11:29 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

neurovive pharmaceutical (NVP) Snapshot

Open
kr53.50
Previous Close
kr54.50
Day High
kr54.75
Day Low
kr53.00
52 Week High
08/5/14 - kr82.00
52 Week Low
12/27/13 - kr15.92
Market Cap
1.5B
Average Volume 10 Days
152.4K
EPS TTM
kr-1.63
Shares Outstanding
27.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROVIVE PHARMACEUTICAL (NVP)

Related News

No related news articles were found.

neurovive pharmaceutical (NVP) Related Businessweek News

No Related Businessweek News Found

neurovive pharmaceutical (NVP) Details

NeuroVive Pharmaceutical AB (publ) researches and develops mitochondrial-protecting pharmaceuticals in Sweden and Hong Kong. Its product portfolio includes CicloMulsion, a drug candidate, which is in Phase III clinical study for reperfusion injury in vasodilation and vasoreinforcement following myocardial infarction; and NeuroSTAT, a drug candidate that is in Phase IIa clinical study for the treatment of traumatic brain injuries. The company is also developing NVP019, an intravenous formulation that is in pre-clinical phase treatment of acute cardiovascular disease and acute brain injury; NVP014 for the treatment of acute ischemic stroke; and NVP015, an orphan drug, which is in pre-clinical development phase for the treatment of primary mitochondrial diseases. It has a collaboration agreement with the Isomerase Therapeutics for the development and commercialization of the cyclophilin-inhibiting molecules. The company was founded in 2000 and is headquartered in Lund, Sweden.

8 Employees
Last Reported Date: 11/19/14
Founded in 2000

neurovive pharmaceutical (NVP) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr1.6M
Chief Scientific Officer
Total Annual Compensation: kr188.0K
Compensation as of Fiscal Year 2013.

neurovive pharmaceutical (NVP) Key Developments

NeuroVive Pharmaceutical AB and Skåne University Hospital Initiate Collaboration on Clinical Phase II Study on Kidney Protection During Heart Surgery

NeuroVive Pharmaceutical AB has initiated a collaboration with Skåne University Hospital to complete a clinical phase II study on the evaluation of the company's product CicloMulsion(R) regarding its ability to prevent acute kidney injury in 150 patients undergoing heart surgery. Enrolment to the study will begin in the first half of 2015 and is expected to continue until the end of 2016. NeuroVive's product CicloMulsion(R) is already being evaluated in clinical studies focusing on protecting the heart and brain in connection with acute injury (known as NeuroSTAT(R) for brain protection). Drugs that protect the mitochondria also have significant potential to protect high-energy organs like the kidneys during surgery. Two clinical studies have shown that the active substance is safe for heart surgery and provides protection against diffuse injury*. This has led Skåne University Hospital to initiate a clinical study to evaluate the potential for protecting the kidneys using CicloMulsion(R) in cardiac surgery. The study is known as CiPRICS (Ciclosporin to Protect Renal function In Cardiac Surgery) and is a double-blind, randomized and placebo-controlled clinical phase II study to include a total of 150 patients. The patients will be treated with CicloMulsion(R) in connection with coronary artery bypass surgery at the Clinic for Cardiothoracic Surgery at Skåne University Hospital in Lund, Sweden. The study is investigator-initiated and is conducted with support from NeuroVive.

Neurovive Pharmaceutical AB Reports Consolidated and Parent Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

NeuroVive Pharmaceutical AB reported consolidated and parent earnings results for the third quarter and nine months ended September 30, 2014. For the quarter on consolidated basis, the company reported net sales of SEK 7,152,000 compared to other operating income of SEK 723,000 a year ago. Operating loss was SEK 3,845,000 compared to SEK 6,671,000 a year ago. Loss before tax was SEK 3,761,000 compared to SEK 6,751,000 a year ago. Loss for the period was SEK 3,761,000 compared to SEK 6,696,000 a year ago. Loss for the period attributable to Parent company shareholders was SEK 3,451,000 compared to SEK 6,399,000 a year ago. Loss per share before and after dilution was SEK 0.18 compared to SEK 0.33 a year ago. Cash flow from operating activities was negative at SEK 12, 185,000 compared to SEK 6,153,000 a year ago. Acquisition of tangible assets was SEK 66,000 compared to SEK 28,000 a year ago. Acquisition of intangible assets was SEK 3,344,000 compared to SEK 1,841,000 a year ago. For the nine months, on a consolidated basis, the company reported net sales of SEK 7,152,000 compared to SEK 5,335,000 a year ago. Operating loss was SEK 27,801,000 compared to SEK 13,060,000 a year ago. Loss before tax was SEK 27,328,000 compared to SEK 12,957,000 a year ago. Loss for the period was SEK 27,328,000 compared to SEK 12,957,000 a year ago. Loss for the period attributable to Parent company shareholders was SEK 26,241,000 compared to SEK 13,793,000 a year ago. Loss per share before and after dilution was SEK 1.07 compared to SEK 0.72 a year ago. Cash flow from operating activities was negative at SEK 42,326,000 compared to SEK 14,457,000 a year ago. Acquisition of tangible assets was SEK 29,000 compared to SEK 28,000 a year ago. Acquisition of intangible assets was SEK 15,383,000 compared to SEK 7,742,000 a year ago. For the quarter, on a parent basis, the company reported net sales of SEK 7,174,000. Operating loss was SEK 2,866,000 compared to SEK 5,675,000 a year ago. Loss before tax was SEK 2,729,000 compared to SEK 5,705,000 a year ago. Loss for the period was SEK 2,729,000 compared to SEK 5,705,000 a year ago. For the nine months, on a parent basis, the company reported net sales of SEK 7,546,000. Operating loss was SEK 24,333,000 compared to SEK 15,978,000 a year ago. Loss before tax was SEK 23,706,000 compared to SEK 15,741,000 a year ago. Loss for the period was SEK 23,706,000 compared to SEK 15,741,000 a year ago.

NeuroVive Signs $150 Million Agreement with OnCore BioPharma for the Out Licensing of NVP018 for the Treatment of Chronic Hepatitis B Virus Infection

NeuroVive Pharmaceutical AB has signed an exclusive global outlicensing agreement with OnCore BioPharma Inc. related to the development and commercialization of NeuroVive's drug candidate NVP018 for oral treatment of chronic Hepatitis B Virus (HBV) infection. The agreement can give NeuroVive in total $150 million in conditional milestone payments plus royalties on future drug sales. The licensing agreement provides OnCore with the exclusive global rights to develop oral formulations of NVP018 for the treatment of chronic Hepatitis B infection. The compensation to NeuroVive consists of an initial upfront payment plus a number of conditional payments based on pre-determined milestones and as well payments relating to sales targets. In addition, NeuroVive will receive incremental royalty payments based on gross revenue from future sales of NVP018. The total value of the agreement is $150 million excluding royalty payments. The exact terms of the agreement regarding payments and royalty figures are not disclosed. NVP018 is an orally-available, sangamide-based, second generation cyclophilin inhibitor with a well-differentiated preclinical profile when compared to other cyclophilin inhibitors. Data presented in April at The International Liver Congress(TM) 2014, the annual meeting of the European Association for the Study of the Liver (EASL), showed that NVP018 appears to inhibit the Hepatitis B virus by two mechanisms in vitro. Hepatitis B is a serious infection of the liver caused by the Hepatitis B virus (HBV) and is considered a major global health problem. Hepatitis B infection can cause chronic liver disease, which increases a patient's risk of death from liver cirrhosis and liver cancer. Estimates from the Centers for Disease Control and Prevention (CDC) indicate that up to 350 million people globally may be chronically infected with Hepatitis B and, according to the World Health Organization (WHO), more than 780,000 people die every year due to Hepatitis B. Most currently-available therapies aim to suppress this viral infection but do not lead to a cure in the overwhelming majority of patients. Identifying a functional or complete cure for Hepatitis B infection remains a significant area of unmet medical need.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVP:SS kr53.00 SEK -1.50

NVP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVP.
View Industry Companies
 

Industry Analysis

NVP

Industry Average

Valuation NVP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 119.4x
Price/Book 11.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 166.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROVIVE PHARMACEUTICAL, please visit www.neurovive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.